NCT07768124Recruiting
Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 11 Aug 2026
- Start date
- 15 Jul 2026
- Primary completion date
- 15 Oct 2026
- Lead sponsor
- Xiu Huang
- Diseases
- Lung cancer
- NCT number
- NCT07768124
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 15 Jul 2026 to the primary completion date, 15 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another interventional clinical trial within 30 days prior to enrollment.
Other illness
- Known allergy to any component of the acupoint plaster.
- Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women.
- Cognitive impairment or psychiatric disorder that prevents completion of study assessments.
Who the study is looking for
- Pathologically or cytologically confirmed lung cancer.
- Scheduled to receive first-line platinum-based chemotherapy.
- Aged 18 to 75 years.
- Karnofsky Performance Status (KPS) score ≥ 60.
- Expected survival ≥ 3 months.
- Voluntarily signed written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Affiliated Yongchuan Hospital of Chongqing Medical University Coordinator of this site? Confirm its status | Chongqing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.